Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Guinea-Bissau
Guinea-Bissau: Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage was 74.0% in 2024. ▲ Rising
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Guinea-Bissau, 2015–2024
Source: WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data. Measured in %.
Analysis
Guinea-Bissau recorded 74.0% for pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in 2024.
Compared with earlier readings it is up 640.0% over ten years.
Over the whole period, pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Guinea-Bissau peaked at 83.0% in 2016 and was at its lowest, 10.0%, in 2015.
Guinea-Bissau ranks 118th of 146 countries on this measure, in the bottom quarter.
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Guinea-Bissau, year by year
| Year | % | Change |
|---|---|---|
| 2015 | 10.0% | — |
| 2016 | 83.0% | +730.0% |
| 2017 | 79.0% | -4.8% |
| 2018 | 82.0% | +3.8% |
| 2019 | 78.0% | -4.9% |
| 2020 | 74.0% | -5.1% |
| 2021 | 67.0% | -9.5% |
| 2022 | 74.0% | +10.4% |
| 2023 | 74.0% | +0.0% |
| 2024 | 74.0% | +0.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 66.4% | 10.0% | 83.0% | 5 |
| 2020s | 72.6% | 67.0% | 74.0% | 5 |
Countries ranked near Guinea-Bissau
- 115 Cote d'Ivoire 75.0% compare
- 115 Germany 75.0% compare
- 115 Honduras 75.0% compare
- 118 Micronesia (country) 74.0% compare
- 120 Ethiopia 73.0% compare
- 121 North Macedonia 72.0% compare
More health data for Guinea-Bissau
- Un projection of annual infant deaths, annual growth rate -1.67 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.7721 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,070 deaths per 1,000 people (2090)
- Number of infants who die before age 1 941 deaths (2100)
- Population ages 80 and above, female, per capita 0.0023 units per person (2025)
- Population ages 80 and above, male, annual growth rate 3.11 % change on previous year (2025)
- Population ages 80 and above, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 80 and above, male, per capita 0.0014 units per person (2025)
- Pertussis - number of reported cases, gaps filled 0 (2025)
- Pertussis - number of reported cases, per capita 0 units per person (2025)
Frequently asked questions
- What is pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Guinea-Bissau?
- Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage in Guinea-Bissau was 74.0% in 2024, according to WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data.
- What is the highest pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage recorded in Guinea-Bissau?
- The highest recorded value was 83.0% in 2016.
- What is the lowest pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage recorded in Guinea-Bissau?
- The lowest recorded value was 10.0% in 2015.
- How does Guinea-Bissau rank for pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage?
- Guinea-Bissau ranks 118th out of 146 countries with data for 2024.
- Is pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage rising or falling in Guinea-Bissau?
- Over the last ten years it is up 640.0%. The long-run trend across the full record is rising.
- Where does this Guinea-Bissau data come from?
- The figures come from WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data, published as part of Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 10 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Share of one-year-olds who have had the third dose of the pneumococcal conjugate vaccine in a given year.